Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs VanEck Uranium & Nuclear ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while VanEck Uranium & Nuclear ETF trades at $103.53 (market cap $3.51B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 3.6× VanEck Uranium & Nuclear ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and VanEck Uranium & Nuclear ETF for 8 Days on average.
| HALO | NLR | |
|---|---|---|
Market Cap | $12.58B | $3.51B |
Volume | 2,179,278 | 414,516 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $164.37 |
52-Week Low | $61.63 | $102.38 |
Typical Hold Time | 1 Days | 8 Days |
Enterprise Value | $14.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
